Ulcerative Colitis Patients In England Get New Treatment Option
NICE Reverses Initial Rejection Of Janssen’s Stelara
Executive Summary
Stelara is a cost-effective use of National Health Service resources, but only where a TNF-alpha inhibitor has failed or cannot be used, and when the product is offered at the price reduction agreed with the health department’s commercial medicines arm, says the latest advice from England’s health technology assessment body, NICE. The move comes after a similar recommendation made earlier this month by NICE’s counterpart in Scotland.